Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report
M Brunet, T Van Gelder, A Åsberg… - Therapeutic drug …, 2019 - journals.lww.com
Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …
Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation
DRJ Kuypers, Y Le Meur, M Cantarovich… - Clinical journal of the …, 2010 - journals.lww.com
With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …
for more accurate drug dosing has become evident. Personalized immunosuppressive …
[HTML][HTML] Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation
MA Sikma, EM Van Maarseveen… - American Journal of …, 2015 - Elsevier
Annually, about 8000 heart and lung transplantations are successfully performed worldwide.
However, morbidity and mortality still pose a major concern. Renal failure in heart and lung …
However, morbidity and mortality still pose a major concern. Renal failure in heart and lung …
Therapeutic drug monitoring of mycophenolate mofetil in transplantation
T Van Gelder, Y Le Meur, LM Shaw… - Therapeutic drug …, 2006 - journals.lww.com
A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …
CYP3A5 and CYP3A4 but not MDR1 Single‐nucleotide Polymorphisms Determine Long‐term Tacrolimus Disposition and Drug‐related Nephrotoxicity in Renal …
DRJ Kuypers, H De Jonge, M Naesens… - Clinical …, 2007 - Wiley Online Library
The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …
[HTML][HTML] Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled …
R Bouamar, N Shuker, DA Hesselink, W Weimar… - American Journal of …, 2013 - Elsevier
Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the
concentration–effect relationship for Tac is poorly defined. This study investigated whether …
concentration–effect relationship for Tac is poorly defined. This study investigated whether …
[HTML][HTML] AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients
EM Scholten, SCLM Cremers, RC Schoemaker… - Kidney international, 2005 - Elsevier
AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal
transplant recipients. Background Tacrolimus has a narrow therapeutic window, and …
transplant recipients. Background Tacrolimus has a narrow therapeutic window, and …
Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention
The immunosuppressive agent mycophenolate is used extensively in kidney transplantation,
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …
Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
W Zhao, V Elie, G Roussey, K Brochard… - Clinical …, 2009 - Wiley Online Library
The aim of this study was to develop a population pharmacokinetic model of tacrolimus in
pediatric kidney transplant patients, identify factors that explain variability, and determine …
pediatric kidney transplant patients, identify factors that explain variability, and determine …